SAFETY OF LONG-TERM OZANIMOD TREATMENT FOR UP TO 4 YEARS BY AGE GROUP IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION

被引：0
|
作者：
Siegel, Corey A.
Rubin, David T.
Long, Millie D.
Danese, Silvio
Cross, Raymond K.
Armuzzi, Alessandro
Dignass, Axel
Kobayashi, Taku
Faye, Adam S.
Lama, Sonie
Charles, Lorna
Cetin, Volkan
Petersen, AnnKatrin
Wu, Hsiuanlin
Wang, Dong
Jain, Anjali
Sabino, Joao
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1771
引用
收藏
页码：S805 / S806
页数：2
相关论文
共 50 条
  • [21] Efficacy and Safety of Upadacitinib After 3 Years of Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Long-Term Data From the Phase 3 Open-Label Extension Study (U-ACTIVATE)
    Panaccione, Remo
    Higgins, Peter
    Nakase, Hiroshi
    Glover, Sarah C.
    Danese, Silvio
    Colombel, Jean-Frederic
    Eccleston, Jason
    Kujawski, Michelle
    Remple, Valencia
    Yao, Xuan
    Suravaram, Smitha
    Schreiber, Stefan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10): : S1061 - S1062
  • [22] Efficacy and safety up to 3 years of risankizumab maintenance treatment in patients with moderately to severely active ulcerative colitis: interim results from phase 3 COMMAND open-label extension study
    Atreya, R.
    Louis, E.
    Loftus Jr., E., V
    Rubin, D. T.
    Dubinsky, M.
    Hisamatsu, T.
    Kalabic, J.
    Mendez, P.
    Chen, S.
    Shah, S.
    Morisset, P.
    Duan, W. R.
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i104 - i106
  • [23] Impact of Prior Biologic Exposure on the Durability of Ozanimod Over 5 Years of Continuous Treatment in Patients With Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension Study
    Sands, Bruce E.
    Oneto, Caterina
    Borman, Zachary A.
    Syal, Gaurav
    Ungaro, Ryan C.
    Ferrante, Marc
    Lindsay, James O.
    Blumenstein, Irina
    Liu, Zhaohui
    Mehra, Dimpy
    Jain, Anjali
    D'Haens, Geert R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1042 - S1042
  • [24] SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS OVER TIME: POOLED ANALYSIS FROM PHASE 2, PHASE 3, AND OPEN-LABEL EXTENSION TRIALS
    D'Haens, Geert R.
    Colombel, Jean Frederic
    Lichtenstein, Gary R.
    Charles, Lorna
    Petersen, AnnKatrin
    Ather, Shabana
    Kollengode, Kanthi
    Hsu, Kate
    Irving, Peter M.
    Danese, Silvio
    GASTROENTEROLOGY, 2021, 160 (06) : S35 - S35
  • [25] Long-Term Clinical and Endoscopic Outcomes in True North Week 52 Clinical Remitters Over 3 Years of Treatment With Ozanimod: An Interim Analysis of the True North Open-Label Extension Study
    Afzali, Anita
    Rubin, David T.
    Abreu, Maria T.
    Chiorean, Michael V.
    Akukwe, Lucy
    Jain, Anjali
    Petersen, AnnKatrin
    Osterman, Mark T.
    Wu, Hsiuanlin
    Danese, Silvio
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S630 - S631
  • [26] Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment
    Sandborn, William J.
    Lawendy, Nervin
    Danese, Silvio
    Su, Chinyu
    Loftus, Edward V., Jr.
    Hart, Ailsa
    Dotan, Iris
    Damiao, Aderson O. M. C.
    Judd, Donna T.
    Guo, Xiang
    Modesto, Irene
    Wang, Wenjin
    Panes, Julian
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (04) : 464 - 478
  • [27] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 4.9 Years of Treatment
    Lichtenstein, Gary R.
    Loftus, Edward V., Jr.
    Bloom, Stuart
    Lawendy, Nervin
    Chan, Gary
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S328 - S328
  • [28] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 5.5 Years of Treatment
    Lichtenstein, Gary R.
    Loftus, Edward V., Jr.
    Soonasra, Arif
    Lawendy, Nervin
    Chan, Gary
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Bloom, Stuart
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S413 - S414
  • [29] Long-term Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis (UC) and Relapsing Multiple Sclerosis (RMS) Studies
    Rubin, David T.
    Wolf, Douglas C.
    Alekseeva, Olga
    Charles, Lorna
    Afsari, Sonia
    Petersen, Ann Katrin
    Sheffield, James
    Li, Hongjuan
    Silva, Diego
    Lublin, Fred D.
    Cree, Bruce
    Cohen, Jeffrey
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S396 - S396
  • [30] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Krakovich, A.
    Sheffield, J. K.
    Cheng, C. -Y.
    Minton, N.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 359 - 360
12345